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Survival of Male Patients with Incontinentia Pigmenti Carrying a Lethal
Mutation Can Be Explained by Somatic Mosaicism or Klinefelter Syndrome
The International IP Consortium*
Incontinentia pigmenti (IP), or “Bloch-Sulzberger syndrome,” is an X-linked dominant disorder characterized by
abnormalities of skin, teeth, hair, and eyes; skewed X-inactivation; and recurrent miscarriages of male fetuses. IP
results from mutations in the gene for NF-kB essential modulator (NEMO), with deletion of exons 4–10 of NEMO
accounting for 180% of new mutations. Male fetuses inheriting this mutation and other “null” mutations ofNEMO
usually die in utero. Less deleterious mutations can result in survival of males subjects, but with ectodermal dysplasia
and immunodeficiency. Male patients with skin, dental, and ocular abnormalities typical of those seen in female
patients with IP (without immunodeficiency) are rare. We investigated four male patients with clinical hallmarks
of IP. All four were found to carry the deletion normally associated with male lethality in utero. Survival in one
patient is explained by a 47,XXY karyotype and skewed X inactivation. Three other patients possess a normal
46,XY karyotype. We demonstrate that these patients have both wild-type and deleted copies of the NEMO gene
and are therefore mosaic for the common mutation. Therefore, the repeat-mediated rearrangement leading to the
common deletion does not require meiotic division. Hypomorphic alleles, a 47,XXY karyotype, and somatic mo-
saicism therefore represent three mechanisms for survival of males carrying a NEMO mutation.
Introduction
Incontinentia pigmenti (IP), or “Bloch-Sulzberger syn-
drome” (MIM 308310), is an X-linked dominant dis-
order characterized by abnormalities of ectodermal
tissue. Typically, IP presents in four dermatologically rec-
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ognized stages: (1) early blistering with eosinophilia, (2)
eruption of hyperkeratotic lesions, (3) hyperpigmenta-
tion along the lines of Blaschko and, finally, (4) dermal
scarring. Abnormal tooth eruption, malformed tooth
crowns, and patchy alopecia are commonly seen, and
retinal dysplasia can sometimes lead to visual problems.
In ∼10% of cases, there may be neurological problems
such as seizures, spasticity, or mental retardation (Landy
and Donnai 1993). The vast majority of female patients
with IP exhibit skewed X-inactivation patterns in blood
and fibroblasts, following selective loss of cells express-
ing the mutated IP gene (Parrish et al. 1996). In these
tissues, cell loss coincides with birth, since neonatal skin
and cord blood may still possess cells expressing the
mutated X chromosome.
We have shown that IP results from mutations in the
gene for NF-kB essential modulator (NEMO) (The In-
ternational Incontinentia Pigmenti Foundation 2000).
Moreover, an intrachromosomal rearrangement that de-
letes exons 4–10 of NEMO (NEMOD4–10), accounts
for ∼83% of new mutations. This mutation is readily
detectable either by the appearance of a novel 8-kb
HindIII band in Southern blot analysis or by a di-
agnostic PCR that yields a 2-kb product from the
NEMOD4–10 allele. NEMO is a component of the IkB
kinase (IKK) complex, which is indispensable for acti-
vation of the NF-kB transcription factor (Rothwarf et
al. 1998; Yamaoka et al. 1998). One function of NF-
kB activity is the protection of cells against apoptosis
induced by tumor necrosis factor (TNF) (Van Antwerp
et al. 1996). Skewed X inactivation in female patients
is therefore assumed to result from the apoptosis of cells
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that have no protection against cell death and the sur-
vival and proliferation of cells expressing the healthy X
chromosome. IP is classically considered a male-lethal
disorder, and many women with IP have recurrent early
miscarriages. Extrapolating from studies of NEMO
knockout mouse lines, in utero lethality of hemizygous
male fetuses is likely to be due to a lack of protection
against apoptosis, particularly in the liver, where TNF
levels are high (Rudolph et al. 2000). Surviving male
patients with IP have not been described in families
carrying either the common deletion or other mutations
predicted to inactivate NEMO protein function. How-
ever, less deleterious (hypomorphic) mutations can give
rise to surviving males. These patients present with a
phenotype quite distinct from IP, which includes ecto-
dermal dysplasia and immunodeficiency with or with-
out lymphedema and osteopetrosis (Zonana et al. 2000;
Aradhya et al. 2001; Doffinger et al. 2001; Jain et al.
2001; Mansour et al. 2001). Female carriers of these
mild mutations may be asymptomatic or have clinical
signs of IP. Male patients with a clinical presentation
that resembles that of female patients with IP—that is,
the characteristic four dermatological stages coupled
with dental and ocular abnormalities—are rarely re-
ported. Several such patients have been found to have
a 47,XXY karyotype and Klinefelter syndrome. How-
ever, male patients with IP and a normal karyotype have
also been described (reviewed by Scheuerle [1998]).
In this article, we describe four boys who presented
with a clinical picture typical of female IP. In all four
patients, the presence of the common NEMO deletion
normally associated with male lethality is detectable. In
one patient, a 47,XXY karyotype and skewed X inac-
tivation provides protection against the morbid effects
of the mutation. The other three karyotypically normal
(46XY) patients acquired the NEMOD4–10 deletion
postzygotically and are somatic—and, potentially, germ
cell—mosaics. Hypomorphic mutation, abnormal kar-
yotypes, and mosaicism, therefore, provide three mech-
anisms for survival of males carrying a mutation at the
IP locus.
Methods
Patient Samples
All patient samples and clinical details were obtained
after consent and local ethical-committee approval.
Fluorescence In Situ Hybridization (FISH)
A lymphoblast culture was prepared from a peripheral
blood sample, and the cells were harvested for FISH.
FISH was performed according to the manufacturer’s
suggestions (Vysis). The X and Y whole-chromosome
paints were directly labeled in Spectrum Orange and
Spectrum Green, respectively.
X-Inactivation Analysis
DNA from peripheral blood was analyzed to deter-
mine X-inactivation status, using a method reported
elsewhere (Parrish et al. 1996). In brief, 250 ng of ge-
nomic DNA from patients was digested overnight with
the methylation-sensitive HpaII enzyme or with a con-
trol enzyme, RsaI. Fifty nanograms of the digest was
used in a PCR to amplify the polymorphic (CAG)n repeat
of the human androgen receptor (HUMARA) locus. The
HpaII restriction site is within the PCR amplicon and
prevents amplification, if digested. Thus, only the meth-
ylated, inactive X chromosome is detected, and the poly-
morphism allows determination of which X chromo-
some is active or inactive.
Detection of NEMOD4–10 by PCR and Southern
Analysis
Detection, by PCR, of the NEMOD4–10 rearrange-
ment was performed using the protocol described else-
where (The International Incontinentia Pigmenti Foun-
dation 2000). Long-range PCR (EXPAND, Roche Mo-
lecular Biochemicals), with primers 3FH (GACCAGCTC-
CCCTCCACTGTC) and JF3R (CTCGGAGACACAGG-
AACCAGCA), produces a 2-kb product only if the re-
arrangement is present. The wild-type fragment of ∼13
kb is seen in male or female samples that do not carry
the mutation but is rarely seen in heterozygotes, since
amplification of the 2-kb product predominates. A mod-
ified protocol that utilizes a forward primer closer to the
boundary of rearrangement was used for detection of the
rearrangement in patient 4, in whom DNA was refractory
to amplification of the 2-kb product by 3FH and JF3R.
The details of this method are in preparation and are
available from the authors on request. For Southern anal-
ysis, 7 mg of DNA was digested with HindIII and was
resolved on 0.7% agarose in 1#Tris-borate/EDTA. DNA
was transferred in 20# saline sodium citrate to immo-
bilon NY (Millipore) membrane and was UV cross
linked at 40,000 joules with a Stratalinker (Stratagene).
NEMO gene fragments were detected by hybridization
to NEMO probes specific to exon 2 or exon 3 of the gene
(GenBank accession number AJ271718). Exon 2 is not
present in the pseudogene. Exons 2 and 3 are contained
on a novel 8-kb HindIII fragment produced as a result of
the NEMOD4–10 rearrangement.
PCR Detection of the Wild-Type NEMO Gene
For specific detection of the undeleted NEMO gene,
amplification between intron 2 (GAG GAC CAA TAC
CGA GCA TC) and exon 4 (ACC CTC CAG AGC CTG
GCA TTC ) or between exon 2 (CCCTTGCCCTGTTG-
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Figure 1 Analysis of family XL409. A, Three-generation pedi-
gree, with the arrow indicating the proband. B, Southern blot analysis
showing the mutant 8-kb fragment in affected members and only a
normal 12-kb band in unaffected individuals. The blot is a HindIII
digest hybridized with a probe unique to exon 2 in the functional copy
of NEMO (GenBank accession number AJ271718). An unaffected
negative control (-C) is included on the blot, in addition to positive
controls for the female patient with an IP deletion (FC) and a spon-
taneous male abortus (MC). C, Chromosome painting using X- and
Y-specific probes, which confirms a 47,XXY karyotype in the proband.
The X and Y whole-chromosome paints are directly labeled in Spec-
trum Orange and Spectrum Green, respectively (Vysis). D, X-inacti-
vation analysis of DNA extracted from peripheral blood, using the
HUMARA (CAG)n polymorphism, showing complete skewing in af-
fected individuals. The assay detects the inactive X chromosome be-
cause it is methylated; two bands in the HpaII (H) lanes reflect random
X-inactivation, and a single band indicates complete skewing. TheRsaI
(R) digest serves as a control.
GATGAA) and intron 4 (AACCCTGGAAGGGGTCTC-
CGGAG) was performed. Amplification was performed
using system 3 of the long-range PCR EXPAND kit, with
annealing at 65C.
Results
Patient 1 (XL409-05, United States)
Patient 1 is a 1-year-old male child (fig. 1a) who
developed, between the ages of 10 d and 4 wk, vesicles
on the right arm, on the dorsum of each leg, and in
the interdigital areas on the right hand and right foot.
A skin biopsy confirmed marked dyskeratosis and eo-
sinophilic infiltration consistent with IP. All lesions
progressed to become papules, warty hyperkeratosis,
and linear hyperpigmentation. A small area of alo-
pecia was noted on the left parietotemporal area of
the scalp. The other affected members of this family,
XL409, are all female, and they demonstrated similar
skin abnormalities. Southern blot analysis revealed
that all affected individuals, including XL409-05, car-
ried the NEMOD4–10 male-lethal deletion associated
with 83% of IP cases (indicated by the appearance of
the 8-kb band in fig. 1b). Interestingly, XL409-05 also
showed a normal band (12 kb) on this blot, suggesting
that he had two X chromosomes. FISH confirmed a
47,XXY karyotype (fig. 1c). Finally, polymorphism
analysis revealed that XL409-05 had complete skew-
ing of X inactivation, similar to that in his affected
female relatives (fig. 1d). The same polymorphism also
indicated that the proband’s extra X chromosome was
inherited from his father and originated from a non-
disjunction event during the first meiotic division in
the paternal germline (fig. 1d).
Patient 2 (IP114m, United Kingdom)
Patient 2, a boy with no family history of IP, had fluid-
filled blisters at birth, on the ankles, chin, and in the
groin, that were negative for bacteria or viruses. At age
1 mo the blisters had resolved, and he had developed
white, plaque-like lesions on his arms, legs, and face (fig.
2). A skin biopsy showed massive epithelial cell prolif-
eration, dyskeratotic cells, and infiltration of eosino-
phils, leading to a diagnosis of IP. Fibroblasts from this
biopsy were used to determine a 46,XY karyotype. His
hyperkeratotic lesions persisted for 11 year but became
confined to the feet. Walking was delayed, because of
the lesions on his soles. Hyperpigmentation was evident
at age 1 mo and became extensive, following Blaschko’s
lines, particularly on the back and legs, over the next 5
years. This condition faded, but at age 9 years he has
retained areas of hyperpigmentation and extensive scar-
ring (fig. 2). He is severely hypodontic, with several mal-
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Figure 2 Clinical presentation of IP114m. Blistering and plaque-like lesions on the hands (A) and face (B), at age 1 mo. Streaks of
hyperpigmentation and scarring on the trunk (C) and legs (D) at age 10 years.
formed crowns, and he has sparse hair and eyebrows
and some atrophic skin on his scalp. His neurological
development is normal. At age 9 years, he presented with
painless loss of vision in the left eye, which was due to
spontaneous vitreous hemorrhage. His vision returned
after 6 d, and fundoscopy revealed preretinal scarring,
fibrosis in the temporal periphery, telangiectasia, and
pigment epithelial mottling. Bilateral corneal opacity
was also noted.
A PCR diagnostic for the NEMOD4–10 rearrange-
ment clearly showed the presence of this mutation in
DNA extracted from the proband’s blood (taken at age
9 years) and neonatal fibroblast line (fig. 3A) but not in
DNA from his mother. Advantage was also taken of the
fact that NEMOD4–10 deletes exons 4–10 and the ob-
servation that the NEMO pseudogene does not contain
exon 2. Through use of primers in exon 2 and in intron
4 of the NEMO gene, a 6.7-kb fragment specific to wild-
type NEMO was obtained, confirming the presence of
an intact NEMO gene in the patient (fig. 3B). Southern
blot analysis of DNA from neonatal fibroblasts showed
the 8-kb HindIII band representing the NEMOD4–10
rearrangement to be present at approximately the same
intensity as the wild-type 12-kb fragment (fig. 3C). Note
that the lower band of the 12-kb doublet is part of the
NEMO gene, and the upper band belongs to the X-
linked homologous NEMO pseudogene that contains
exons 3–10. Thus, IP114m is heterozygous—and, there-
fore, mosaic—for the NEMOD4–10 mutation. Interest-
ingly, the rearrangement was not detectable by Southern
analysis of blood DNA. X chromosomes carrying the
mutation are therefore present at a much lower level in
the blood sample taken at age 9 years (detectable only
by PCR), compared to level in the neonatal fibroblast
line. This is consistent with the hypothesis that cells pos-
sessing the mutation undergo uncontrolled apoptosis.
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Figure 3 A, PCR to detect NEMOD4–10, using primers that
span the deletion breakpoint, as described in the Methods section.
Template DNAs are as follows: lane 1, blood DNA from 9-year-old
IP114m; lane 2, IP114m neonatal fibroblast line; lane 3, unaffected
mother of IP114m; lane 4, a known female carrier of NEMOD4–10;
and lane 5, a healthy female control. B, PCR detection of the wild-
type NEMO gene, using primers in exon 2 and intron 4 to give a 6.7-
kb band. Lane 1, IP114m; lane 2, mother of IP114m; and lane 3,
healthy female control. C, Detection of NEMO HindIII fragments by
Southern blot analysis. NEMO fragments are detected by hybridiza-
tion to a probe encoding exon 3. Lane 1, blood DNA from 9-year-
old IP114m; lane 2, IP114m neonatal fibroblast line; lanes 3 and 6,
DNA from healthy female controls; lane 4, DNA from a spontaneous
male abortus carrying only the NEMOD4–10 allele; lane 5, DNA from
a female IP carrier of the NEMO deletion. Note that there is a doublet
at ∼12 kb, representing digestion products from the NEMO bona fide
(lower band) and pseudo-genes (upper band). For the male subject in
lane 4, who is hemizygous for the NEMOD4–10 mutation, the lower
12-kb band, representing the wild-type gene, has disappeared, whereas
IP114m (lanes 1 and 2) still has the wild-type allele and is therefore
mosaic.
Patient 3 (IP-LN, Italy)
Patient 3 was born after a normal pregnancy. Family
history was negative for IP, skin and neurological dis-
orders, and miscarriages. At birth, erythematous blisters
were scattered over the body surface, particularly on the
upper and lower extremities and on the back and axillae
in a swirled pattern, according to the distribution of
Blaschko’s lines. His mother was carefully examined,
and no dental, hair, or skin anomalies were seen. Mu-
cosae, C-reactive protein, blood culture, and skin swabs
were all normal, and skin treatment with local antibi-
otics was not successful. Complete blood counts showed
eosinophilia of 790/mm3. At 10 d, a skin biopsy sug-
gested a diagnosis of IP. Subsequent cardiac, head, and
abdominal ultrasound, electroencephalogram, chest X-
rays, and eye examinations were normal, and his kar-
yotype was 46,XY. At 30 d, several skin lesions resolved
without scars, and some warty lesions, similar to those
observed for case 1, were evident on the hands. At age
3 mo, the infant was feeding and growing well, neu-
rological development was normal, and the warty lesions
were no longer evident. At age 5 mo, linear yellowish
streaks were present in those areas previously marked
by vesicular lesions. At age 23 mo, the child is growing
well, shows very light yellowish streaks on the skin, has
a conic tooth in his mouth, and shows normal neuro-
logical development.
DNA from patient peripheral blood lymphocytes was
analyzed by PCR for the presence of NEMOD4–10
(The International Incontinentia Pigmenti Foundation
2000). DNA from the male patient yielded the specific
2-kb PCR product diagnostic for this mutation (fig.
4A), whereas his parents’ DNA was negative for the
NEMOD4–10 rearrangement. To explain the survival
of this patient, the presence of the normal X chro-
mosome was confirmed. Through use of primers in in-
tron 2 and in exon 4 of the NEMO gene, a 3.3-kb
fragment specific for wild-type NEMO was obtained
from peripheral blood DNA (fig. 4b). Moreover, in
DNA from an Epstein-Barr virus–transformed lympho-
cyte cell line, only the normal X chromosome was de-
tected. This suggests negative selection against the cells
carrying the mutation in cell culture.
Patient 4 (IPTC, France)
Patient 4 had no antecedents with IP but presented at
birth with a vesicular rash on the trunk and limbs. Bi-
opsy revealed typical IP histology, with hypereosino-
philia but a normal 46,XY karyotype. He went on to
develop areas of hyperpigmentation. At age 8 wk, he
had epileptic episodes that were controlled by medica-
tion. A brain scan revealed an ischemic lesion. At age 8
mo, subsequent to a viral infection, he developed a sec-
ond episode of blistering, with lesions located on the
primary scars. At age 5 years, he is severely mentally
retarded.
The presence of the common mutation in DNA from
the proband’s blood was not detectable when the pre-
viously described diagnostic assay was used, but it
was confirmed using a new protocol diagnostic for the
NEMOD4–10 rearrangement. This yields a smaller
product (1 kb) in the presence of the mutation (fig.
5). Even when this protocol was used, detection of
NEMOD4–10 required inclusion of 1–2 mg of DNA in
the reaction. This suggests that the level of mosaicism
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Figure 4 A, Diagnostic PCR yields a 2-kb band in patients with IP and a 13-kb band in controls. DNA templates are as follows: lane 1,
patient peripheral blood lymphocytes; lane 2, patient immortalized lymphocyte cell line; lane 3, mother’s lymphocytes; lanes 4 and 5, female
patients with IP; lane 6, healthy sample. B, Amplification between the intron-2 forward primer and a primer from exon 4, giving a band at
3.3 kb only from wild-type NEMO. DNAs are from patient’s immortalized lymphocyte cell line (lane 1), patient’s peripheral blood lymphocytes
(lane 2), healthy sample (lane 3), mother’s DNA (lane 4), and female patients with IP (lanes 5 and 6).
Figure 5 Presence of NEMOD4–10 in DNA from the blood of
patient 4, using a new protocol that yields a 1.04-kb product in the
presence of the mutation. Lanes 1–3 contain the products obtained
from using 500–2,000 ng of template DNA. Lanes 4–6 show absence
of the mutation-specific band in samples from healthy subjects. The
lower 733-bp band is an internal control for DNA quality.
in the blood of this patient was low. The available DNA
was insufficient for Southern analysis.
Discussion
Although IP is classified as a male-lethal X-linked dom-
inant disorder, a small number of surviving male patients
have been reported, some within families with typically
affected female patients (Scheuerle 1998). A 47,XXY
karyotype is one mechanism by which males may survive
the effects of inheriting a lethal IP mutation, since this
establishes a heterozygous genotype that is compatible
with survival. Several cases of IP have been reported in
47,XXY patients (Kunze et al. 1977; Ormerod et al.
1987; Prendiville et al. 1989; Garcia-Dorado et al. 1990;
Fowell et al. 1992; Kirchman et al. 1995; Scheuerle
1998). Here we provide the first molecular confirmation
that IP in these cases can result from inheritance of a
mutation in NEMO, and we provide the first description
of skewed X inactivation in a 47,XXY male patient. In
this patient, only the paternal X is active in most cells,
since the maternal X carries the IP mutation. If the X
chromosome carries imprinted genes, this may have a
bearing on the eventual Klinefelter syndrome–associated
phenotype in this patient, since the skewed X inactiva-
tion leads to expression from the same X chromosome
in all of his affected cells.
Three surviving 46,XY male patients possessing a
NEMO mutation as well as a wild-type gene had typ-
ical sequential IP skin stages. Interestingly, in all three
cases the postzygotic mutation is the common deletion,
NEMOD4–10, caused by rearrangement between tan-
dem repeats in intron 3 and downstream of the NEMO
gene (The International Incontinentia Pigmenti Foun-
dation 2000). A predominantly paternal origin for this
mutation in families with IP (The International Incon-
tinentia Pigmenti Foundation 2000; authors’ unpub-
lished observations) suggests that the mutation occurs
primarily through intrachromosomal exchange rather
than through misalignment of repeats during meiosis (a
copy of NEMO is not found on the Y chromosome).
The finding that this mutation is not restricted to meiotic
divisions but can occur in mitotic cells supports this
conclusion. Furthermore, the mutational mechanism is
unlikely to involve half-chromatid (single DNA strand)
exchange, as proposed by Lenz (1975) to explain IP in
male subjects, since recombination between repeats re-
quires the interaction of DNA duplexes (whole chro-
matid). Interestingly, postzygotic inversion between re-
peat sequences in a female carrier of a factor VIII
mutation has also recently been described (Oldenburg
et al. 2000).
Postzygotic mutation and somatic mosaicism is be-
coming increasingly recognized as a mechanism for ex-
plaining unusual haplotype segregation or the pheno-
type of male subjects carrying X-linked dominant
mutations. For example, somatic mosaicism was re-
cently reported for surviving male patients carrying mu-
tations in the genes for the X-linked dominant diseases
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Rett syndrome and Conradi-Hu¨nermann-Happle syn-
drome (CDPX2) (Clayton-Smith et al. 2000; Has et al.
2000). Interestingly, both CDPX2 and IP have been de-
scribed as displaying “anticipation,” a term used to de-
scribe an increase in disease severity with the number
of generations (Carney 1976; Traupe et al. 1992). So-
matic and gonadal mosaicism in individuals at the top
of pedigree provides an explanation for these obser-
vations. Moreover, given that the mutational mecha-
nism giving rise to most cases of IP is repeat-mediated
deletion, mosaicism is likely to be quite a common oc-
currence and to account for some of the extremely mild
presentation in some female IP obligate mutation car-
riers (Woffendin et al. 1999). Somatic and/or germ line
mosaicism in parents of patients with apparently spo-
radic IP should therefore always be considered when
investigating families with IP.
In summary, karyotypic analysis and examination of
the NEMO gene are, therefore, strategies for the in-
vestigation of male patients with IP symptoms. Since
the NEMOD4–10 rearrangement is the most likely mu-
tation, this should be sought initially. Furthermore, the
subsequent selection against mutation-bearing cells in-
dicates that, where possible, neonatal DNA samples
from blood as well as from affected tissue should be
used for DNA analysis.
The boys described in this report presented with florid
signs of IP, probably because the mutational event oc-
curred early in development. It is likely that, depending
on the timing and location of somatic rearrangement of
NEMO, male patients with very localized skin lesions
will also exist. Since this article was prepared, three
additional male carriers of NEMOD4–10 with clinical
signs of IP have been identified through diagnostic
screening (J. Whittaker, unpublished data).
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